CLINICAL RESEARCH: HEART FAILURE
Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
Roland R. van Kimmenade, MD, PhD*,
James L. Januzzi, Jr, MD, FACC ,
Patrick T. Ellinor, MD, PhD,
Umesh C. Sharma, MB, BS, PhD*,
Jaap A. Bakker, MSc ,
Adrian F. Low, MB, BS,
Abelardo Martinez, MD,
Harry J. Crijns, MD, PhD*,
Calum A. MacRae, MB, ChB, PhD,
Paul P. Menheere, PhD and
Yigal M. Pinto, MD, PhD*,*
* Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
Department of Clinical Chemistry, University Hospital Maastricht, Maastricht, the Netherlands
Manuscript received August 16, 2005;
revised manuscript received January 3, 2006,
accepted March 28, 2006.
* Reprint requests and correspondence: Dr. Yigal M. Pinto, Department of Cardiology and Experimental Cardiology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, the Netherlands. (Email: y.pinto{at}cardio.azm.nl).
OBJECTIVES: This study sought to explore the role of new biomarkers in heart failure (HF).
BACKGROUND: We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF.
METHODS: Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF.
RESULTS: The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone.
CONCLUSIONS: Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF.
|
Abbreviations and Acronyms
| | AUC = area under the curve | | BNP = brain natriuretic peptide | | CAD = coronary artery disease | | CI = confidence interval | | gal = galectin | | HF = heart failure | | IQR = interquartile range | | NT-proBNP = amino-terminal pro-brain natriuretic peptide | | NYHA = New York Heart Association | | OR = odds ratio | | PRIDE = N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department | | ROC = receiver-operating characteristic |
|
This article has been cited by other articles:
|
|
|
|
 
G. M. Felker, M. Fiuzat, L. K. Shaw, R. Clare, D. J. Whellan, L. Bettari, S. C. Shirolkar, M. Donahue, D. W. Kitzman, F. Zannad, et al.
Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study
Circ Heart Fail,
January 1, 2012;
5(1):
72 - 78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lopez-Andres, P. Rossignol, W. Iraqi, R. Fay, J. Nuee, S. Ghio, J. G. F. Cleland, F. Zannad, and P. Lacolley
Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial
Eur J Heart Fail,
January 1, 2012;
14(1):
74 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. J. van Kimmenade and J. L. Januzzi Jr.
Emerging Biomarkers in Heart Failure
Clin. Chem.,
January 1, 2012;
58(1):
127 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. W. Grandin, P. Jarolim, S. A. Murphy, L. Ritterova, C. P. Cannon, E. Braunwald, and D. A. Morrow
Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22
Clin. Chem.,
January 1, 2012;
58(1):
267 - 273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. T. Klip, A. A. Voors, S. D. Anker, H. L. Hillege, J. Struck, I. Squire, D. J. van Veldhuisen, K. Dickstein, and for the OPTIMAAL investigators
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction
Heart,
June 1, 2011;
97(11):
892 - 898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Helske, P. T. Kovanen, J. Lommi, H. Turto, and M. Kupari
Transcardiac gradients of circulating apelin: extraction by normal hearts vs. release by hearts failing due to pressure overload
J Appl Physiol,
December 1, 2010;
109(6):
1744 - 1748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Januzzi Jr., S. Rehman, T. Mueller, R. R. J. van Kimmenade, and D. M. Lloyd-Jones
Importance of Biomarkers for Long-Term Mortality Prediction in Acutely Dyspneic Patients
Clin. Chem.,
December 1, 2010;
56(12):
1814 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Shah, A. A. Chen-Tournoux, M. H. Picard, R. R. J. van Kimmenade, and J. L. Januzzi
Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure
Eur J Heart Fail,
August 1, 2010;
12(8):
826 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. A. Truong, E. Siegel, M. Karakas, J. L. Januzzi Jr., F. Bamberg, A. A. Mahabadi, S. Dasdemir, T. J. Brady, A. Bergmann, J. Kunde, et al.
Relation of Natriuretic Peptides and Midregional Proadrenomedullin to Cardiac Chamber Volumes by Computed Tomography in Patients without Heart Failure: From the ROMICAT Trial
Clin. Chem.,
April 1, 2010;
56(4):
651 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Apostolakis, G. Y.H. Lip, and E. Shantsila
Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?
Cardiovasc Res,
March 1, 2010;
85(4):
649 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-C. Chen, K. D. Tran, and A. S. Maisel
Biomarkers in heart failure
Heart,
February 1, 2010;
96(4):
314 - 320.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R.J. van Kimmenade, A. A. Mohammed, S. Uthamalingam, P. van der Meer, G. M. Felker, and J. L. Januzzi Jr
Red blood cell distribution width and 1-year mortality in acute heart failure
Eur J Heart Fail,
February 1, 2010;
12(2):
129 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. de Boer, A. A. Voors, P. Muntendam, W. H. van Gilst, and D. J. van Veldhuisen
Galectin-3: a novel mediator of heart failure development and progression
Eur J Heart Fail,
September 1, 2009;
11(9):
811 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A.P. Weir, K. S. Chong, J. R. Dalzell, C. J. Petrie, C. A. Murphy, T. Steedman, P. B. Mark, T. A. McDonagh, H. J. Dargie, and J. J.V. McMurray
Plasma apelin concentration is depressed following acute myocardial infarction in man
Eur J Heart Fail,
June 1, 2009;
11(6):
551 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Emdin, S. Vittorini, C. Passino, and A. Clerico
Old and new biomarkers of heart failure
Eur J Heart Fail,
April 1, 2009;
11(4):
331 - 335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Liu, M. D'Ambrosio, T.-d. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. Andre, H.-J. Gabius, and O. A. Carretero
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Am J Physiol Heart Circ Physiol,
February 1, 2009;
296(2):
H404 - H412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, M. R. Mehra, and C. R. deFilippi
Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea
Clin. Chem.,
January 1, 2009;
55(1):
59 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chandrasekaran, O. Dar, and T. McDonagh
The role of apelin in cardiovascular function and heart failure
Eur J Heart Fail,
August 1, 2008;
10(8):
725 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y. Sheikh, H. J. Chun, A. J. Glassford, R. K. Kundu, I. Kutschka, D. Ardigo, S. L. Hendry, R. A. Wagner, M. M. Chen, Z. A. Ali, et al.
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure
Am J Physiol Heart Circ Physiol,
January 1, 2008;
294(1):
H88 - H98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hofstra and S. Heymans
Annexin A5 and the failing heart; lost or found in translation?
Eur. Heart J.,
November 2, 2007;
28(22):
2695 - 2696.
[Full Text]
[PDF]
|
|
|
|
